Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows

statnews.com/2025/05/31/trodelvy-keytruda-breast-cancer-gilead-merck-results

CHICAGO — A treatment that combines two different types of cancer-fighting medicines — Gilead Sciences’ Trodelvy with Merck’s Keytruda — reduced the risk of tumor progression by more than one-third in women with an aggressive form of breast cancer.
The results reported Saturday from the…

This story appeared on statnews.com, 2025-06-01 00:51:37.850000.
The Entire Business World on a Single Page. Free to Use →